Pharma Bio Serv Inc (PBSV) 0.8500 $PBSV Pharma-Bio Serv

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharma Bio Serv Inc (PBSV) 0.8500 $PBSV

Pharma-Bio Serv to Present at 6th Annual LD Micro Invitational Conference on June 8th, 2016
ACCESSWIRE - Tue May 31, 7:30AM CDT
DORADO, PUERTO RICO / ACCESSWIRE / May 31, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that Victor Sanchez, CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 8th, 2016 at 11:30am PST, Track 2 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 8 and 9, 2016.

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2016
ACCESSWIRE - Wed Mar 16, 3:40PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / March 16, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues of $4.9 million for the quarter ended January 31, 2016, a decrease of approximately $1 million, or 17%, when compared to the same period last year. The revenue decrease is mainly attributable to a decline in projects in the Puerto Rico, United States and Europe consulting markets of $0.7, $0.5 and $0.2 million, respectively, partially offset by a gain in the Puerto Rico Lab operation of approximately $0.3 million. Other Company divisions sustained minor revenue gains/losses or remained constant, when compared to the same period last year.

Pharma-Bio Serv Announces Total Net Revenues of $23.4 Million and Net Income of $1.6 Million for the Year Ended October 31, 2015
ACCESSWIRE - Fri Jan 29, 4:13PM CST
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $23.4 million for the year ended October 31, 2015, a decrease of approximately $4.2 million, or 15.1%, when compared to last year. The revenue decrease is mainly attributable to a decline from projects in the United States and Europe consulting markets.

Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2015
ACCESSWIRE - Tue Nov 24, 3:30PM CST
DORADO, PUERTO RICO / ACCESSWIRE / November 24, 2015 / Pharma-Bio Serv, Inc. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that the Company will be a featured presenter at the 8th annual LD Micro Main Event Conference. Victor Sanchez, CEO will present Pharma-Bio Serv's business model and growth strategy at 4:30pm PST on December 2, 2015 in Track 5 at the Luxe Sunset Hotel in Los Angeles, CA.

Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2015
ACCESSWIRE - Mon Sep 14, 3:31PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues for the three and nine months ended July 31, 2015 of $6.2 and $17.5 million, respectively, a decrease of approximately $0.6 and $2.9 million, or 9.6% and 14.3%, respectively, when compared to the same periods last year. The revenue decrease is mainly attributable to declines in the United States and Europe consulting markets of $1.1 and $0.3 million and $4.1 and $0.8 million, for the three months and nine months ended July 31, 2015, as compared to the same periods last year, respectively, partially offset by gains in the Puerto Rico consulting business of approximately $0.8 and $2.0 million, respectively. Latin America projects, managed from Puerto Rico, contributed to Puerto Rico consulting gains in the amount of $0.2 and $1.2 million for the three and nine months ended July 31, 2015, when compared to the same periods last year, respectively.

Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2015
ACCESSWIRE - Mon Jun 15, 4:15PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues for the three and six months ended April 30, 2015 of $5.4 and $11.3 million, respectively, a decrease of approximately $1.1 and $2.3 million, or 17.2% and 16.6%, respectively, when compared to the same periods last year. The revenue decrease is mainly attributable to declines in the United States and Europe consulting markets of $1.4 and $0.2 million, and $2.9 and $0.5, for the three months and six months ended April 30, 2015, as compared to the same periods last year respectively, partially offset by gains in the Puerto Rico consulting business of $0.6 and $1.3 million, respectively. Latin America projects, managed from Puerto Rico, contributed to Puerto Rico consulting gains in the amount of $0.5 and $1.0 million for the three and six months periods ended April 30, 2015 when compared to the same periods last year, respectively.

Pharma-Bio Serv Announces Total Net Revenues of $27.6 Million and Net Income of $2.4 Million for the Year Ended October 31, 2014
ACCESSWIRE - Thu Jan 29, 5:17PM CST
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $27.6 million for the year ended October 31, 2014, a decrease of approximately $5.5 million, or 16.7%, when compared to the same period last year. The revenue decrease is mainly attributable to a decline from consulting projects in the United States and Europe.

Pharma-Bio Serv Appoints Víctor Sánchez as President and Chief Executive Officer Effective January 1, 2015
ACCESSWIRE - Tue Dec 02, 8:01AM CST
DORADO, PUERTO RICO / ACCESSWIRE / December 2, 2014 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, announced today that the Board of Directors has appointed Víctor Sánchez as President and Chief Executive Officer, effective January 1, 2015.
MRK: 59.16 (+1.16)

Pharma-Bio Serv Retains T.R. Winston & Company to Enhance Growth Opportunities Through Business Development, Mergers & Acquisitions, and to Review Strategic Alternatives
ACCESSWIRE - Mon Dec 01, 8:01AM CST
DORADO, PUERTO RICO / ACCESSWIRE / December 1, 2014 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, announced today that it has retained T.R. Winston & Company (T.R. Winston) in order to assist Pharma-Bio Serv in enhancing the Company's growth strategy through business development, and mergers and acquisitions.

Pharma-Bio Serv Signs Strategic Collaboration Agreement With Quality Technical Iberica, S.L.
Marketwired - Thu Oct 09, 3:05PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that it has signed a three-year strategic collaboration agreement with Quality Technical Iberica, S.L ("QTI", a Spain-based company specializing in Calibrations, Validation, HVAC and Clean Room Qualification services.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 7

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 6

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Deadline Looms for Insulet Lawsuit Investors

Updated Category News Views 25

Tick Tock: Investors, Your Clock's Running Out We're not talking about your everyday hiccup here. Insulet Corporation (NASDAQ: PODD) investors have some major decisions to make fast. If there's one deadline you can't afford to sleep through, it's the one coming up on August 31, 2026. That's when folks who've taken a hit investing in Insulet are up to their necks in legal...

Continue Reading
Essential Strategies for Staying Cool This Summer on a Budget

Updated Category News Views 149

Essential Strategies for Staying Cool This Summer on a Budget C & C Heating & Air Conditioning emphasizes a comprehensive approach to reducing energy consumption and maintaining sustainability. C & C Heating & Air Conditioning, a renowned heating and cooling service provider with over seventy years of industry experience, suggests that homeowners can enjoy a cooler...

Continue Reading
F.N.B. Corporation Announces Quarterly Dividend of $0.12

Updated Category News Views 151

F.N.B. Corporation Dividend Announcement F.N.B. Corporation (NYSE: FNB) has officially announced the declaration of a quarterly cash dividend, set at $0.12 per share for its common stock. This move reflects the corporation's strong commitment to rewarding its shareholders and maintaining a solid financial foundation. Details of the Dividend Declaration The dividend is...

Continue Reading
Analyzing Visa's Competitive Edge in Financial Services

Updated Category News Views 231

Understanding Visa's Market Position In a world driven by financial innovation and fierce competition, it's essential for investors and enthusiasts to closely examine the players in the financial services sector. This article delves into Visa (NYSE: V) and contrasts its performance against that of its main competitors. By looking at crucial financial metrics, market...

Continue Reading
Ethereum's Staking Revolution: New Opportunities Await Investors

Updated Category News Views 187

Ethereum's Remarkable Growth and Staking Potential The digital currency scene is buzzing with excitement as Ethereum spot ETFs have recorded impressive weekly inflows reaching $515 million, a notable first in history. This surge in investment highlights Ethereum's growing reputation as a reliable asset favored alike by institutional and retail investors. The Impact of...

Continue Reading